Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care

Expert Rev Cardiovasc Ther. 2021 Mar;19(3):221-236. doi: 10.1080/14779072.2021.1878878.

Abstract

Background: Despite the widespread and increasing use of NOACs in Saudi Arabia, there is a lack of contemporary guidance specific to the region. In particular, guidance on NOAC use in high-risk patients who are more likely to experience bleeding with oral anticoagulant therapy is needed. There is an unmet need for a review of contemporary evidence coupled with expert insights on safe and effective NOAC use in high-risk patients with AF in Saudi Arabia.

Research design and methods: This article provides a detailed review of contemporary literature on NOAC use in high-risk patients with AF. Additionally, key gaps in the literature are identified and expert insights are shared to guide effective management of patients and the significance of local data is evaluated with respect to challenges in optimizing the use of NOACs.

Conclusions: This article provides information that complements and expands on existing reviews and guidelines on NOAC use in patients with AF, with a focus on challenges specific to the Saudi Arabian context with the potential to make a positive contribution to the medical community in Saudi Arabia and in other nations.

Keywords: Middle East region; NOAC; Saudi Arabia; atrial fibrillation; high-risk patients; nvaf.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Hemorrhage / chemically induced*
  • Humans
  • Patient Care
  • Saudi Arabia
  • Stroke / prevention & control

Substances

  • Anticoagulants